According to new forecasts by Frost & Sullivan, the European market for type 2 diabetes drug treatments is set to grow 3.8% yearly, from a value of 9.50 billion euros in 2009 to 15.46 billion euros in 2017. More than 55 million people in Europe were diagnosed with diabetes in 2012, and this figure is
Generic competition and foreign exchange rate has resulted in AbbVie reporting a drop in fourth-quarter sales, however their anti-inflammatory blockbuster Humira continues to soar. The company announced a net income of $1.13 billion, down 27%, while fourth quarter revenues dropped slightly to $5.11 billion. The majority of AbbVie’s revenue was gained from Humira (adalimumab), which
Pfizer yesterday revealed a solid set of fourth-quarter results for 2013, with sales driven by their oncology unit, Lyrica and Enbrel. Net income for the quarter was $2.57 billion, a decrease of 59% on Q4 2012 (which included profits from the sale of their nutritional products business). Group turnover also slipped slightly to $13.56 billion,
The day after announcing a partnership with UK’s Horizon Discovery, AstraZeneca have announced another oncology partnership with Immunocore, a UK biotechnology company. The agreement with Immunocore focuses around Immunocore’s ImmTAC technology. The technology has created a platform of biological medicines which direct a patient’s T cells to specifically destroy only cancerous cells, avoiding damage to
Would you like to know how your salary compares to other employees in similar physician jobs? The results of The Clinical Professionals Group’s 2014 European Pharmaceutical Salary Survey are now available. If you would like a free salary survey results book, contact Daniel Patterson or Donna Wright on +44(0)118 952 2795. Earlier this year, The Clinical Professionals
Only Medics, part of The Clinical Professionals Group, will be closed from the afternoon of Christmas Eve until Thursday 2nd January 2014. This year has been a very successful year for Only Medics, and we would like to take this opportunity to thank all of our clients and candidates, and wish you a very happy
GSK Invests £25 Million into their Montrose, Scotland FacilityGlaxoSmithKline (GSK) have announced that they will invest £25 million to bring production of ingredients for four new pharmaceutical products to their site in Montrose, Scotland. The investment is expected to create 25 new jobs for process technicians, engineers and chemists, increasing the total GlaxoSmithKline workforce in
The Netherlands’ Royal DSM have announced that they have sold their pharmaceutical unit to the US private equity firm, JLL Partners, as part of an agreement worth around $2.60 billion. They plan to set up a new, as-yet-unnamed, organisation that will combine the DSM Pharmaceutical Products (DPP) division with Patheon, a services company that is
Merck & Co have seen revenues drop by 4 per cent in their third quarter, as their diabetes blockbuster, Januvia, continued to show signs of weakness in the US. Sales were reported to be $11 billion, with Merck’s DPP-4 inhibitor Januvia (sitagliptin) down 5% to $927 million. Line extension Janumet (sitagliptin and metformin) fared slightly
Eli Lilly have revealed a positive set of financials for their third quarter of 2013, which was aided by cost-cutting and continued strong sales of Cymbalta. Net income dropped by 9% to $1.20 billion, although it is worth noting that Eli Lilly’s results from Q3 of 2012 included an early payment of $787 million from
